Measurement of Gastric Emptying During and After COLOKIT® Intake

Inclusion criteria

• Subject who signed an informed consent to participate in the trial.
• Subject affiliated with Social Security
• Men and women aged 18 to 75 years.
• Subject with an indication of scheduled outpatient colonoscopy.
• colonoscopy performed within six hours after the second sequence COLOKIT®.
• Subject able to swallow tablets.

Exclusion criteria

• Women pregnant or likely to be (without contraception) or nursing.
• Subject having any of the following diseases or conditions:

• allergy or hypersensitivity to the product tested or any of its excipients,
• nausea, vomiting or abdominal pain,
• clinically significant renal failure,
• primary hyperparathyroidism associated with hypercalcemia,
• congestive heart failure,
• ascites,
• a known or suspected bowel obstruction,
• megacolon (congenital or acquired)
• intestinal perforation,
• ileus,
• an inflammatory disease or suspected inflammatory bowel disease,
• swallowing disorders,
• known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus),
• diabetes mellitus (insulin or non insulin-dependent)
• a history of gastric surgery (partial or total)
• a contraindication to the anesthesia required for the completion of the colonoscopy,
• Any clinical condition which, in the opinion of the investigator, would not allow the subject to perform the test in good conditions.